Encorafenib

Major

Encorafenib Relacorilant Lifyorli Increased CYP3A4 substrate exposure, increased risk of CYP3A4 substrate-related adverse reactions, reduced relacorilant exposure a... Details Encorafenib Remibrutinib Rhapsido Reduced remibrutinib exposure and reduced efficacy of remibrutinib Details Encorafenib Repotrectinib Augtyro Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Revumenib Revuforj An increased risk of QT interval prolongation Details Encorafenib Ribociclib Kisqali Increased encorafenib exposure, an increased risk of encorafenib-related adverse reactions and an increased risk of QT interval pr... Details Encorafenib Rifabutin Mycobutin Reduced encorafenib exposure and reduced efficacy of encorafenib Details Encorafenib Rifampin Rifadin Reduced encorafenib exposure and reduced efficacy of encorafenib Details Encorafenib Rifapentine Priftin Reduced encorafenib exposure and reduced efficacy of encorafenib Details Encorafenib Rilpivirine Edurant An increased risk of QT interval prolongation and torsade de pointes Details Encorafenib Rilzabrutinib Wayrilz Reduced rilzabrutinib exposure, reduced efficacy of rilzabrutinib, increased CYP3A substrate exposure and an increased risk of CYP... Details Encorafenib Risperidone Perseris Increased risk of QT interval prolongation Details Encorafenib Ritlecitinib Litfulo Increased encorafenib exposure and an increased risk of encorafenib-related adverse events Details Encorafenib Ritonavir Norvir Increased encorafenib exposure, an increased risk of encorafenib-related adverse reactions and an increased risk of QT interval pr... Details Encorafenib Rivaroxaban Xarelto Reduced rivaroxaban exposure Details Encorafenib Romidepsin Reduced romiDEPsin exposure Details Encorafenib Rotavirus Vaccine, Live An increased risk of infection by the live vaccine Details Encorafenib Schisandra Sphenanthera Increased encorafenib exposure and an increased risk of encorafenib-related adverse events Details Encorafenib Sebetralstat Reduced sebetralstat exposure and reduced efficacy of sebetralstat Details Encorafenib Segesterone Reduced hormonal contraceptives exposure and reduced efficacy of hormonal contraceptives Details Encorafenib Selpercatinib Retevmo Increased risk of QT interval prolongation Details Encorafenib Selumetinib Koselugo Reduced selumetinib exposure and reduced efficacy of selumetinib Details Encorafenib Sertindole Increased risk of QT interval prolongation Details Encorafenib Sevabertinib Hyrnuo Reduced sevabertinib exposure and reduced efficacy of sevabertinib Details Encorafenib Sevoflurane Petrem Increased risk of QT interval prolongation Details Encorafenib Sildenafil Liqrev Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Siponimod Mayzent An increased risk of QT interval prolongation Details Encorafenib Sirolimus Felycin Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Sodium Phosphate OsmoPrep Increased risk of QT interval prolongation Details Encorafenib Sodium Phosphate, Dibasic Increased risk of QT interval prolongation Details Encorafenib Sodium Phosphate, Monobasic Increased risk of QT interval prolongation Details Encorafenib Solifenacin Vesicare Increased risk of QT interval prolongation Details Encorafenib Sonrotoclax Reduced sonrotoclax exposure and reduced efficacy of sonrotoclax Details Encorafenib Sorafenib Nexavar Increased risk of QT interval prolongation, reduced SORAfenib exposure and reduced antitumor activity of sorafenib Details Encorafenib Sotalol Betapace Increased risk of QT interval prolongation Details Encorafenib Sparsentan Filspari Reduced sparsentan exposure and reduced efficacy of sparsentan Details Encorafenib St John's Wort Reduced encorafenib exposure and reduced efficacy of encorafenib Details Encorafenib Sulpiride Increased risk of QT interval prolongation Details Encorafenib Sultopride Increased risk of QT interval prolongation Details Encorafenib Sunitinib Sutent Altered (increased or reduced) SUNItinib exposure; an increased risk of SUNItinib-related toxicities; reduced efficacy of SUNItini... Details Encorafenib Sunvozertinib Zegfrovy Reduced sunvozertinib exposure and reduced efficacy of sunvozertinib Details